Aortic & peripheral vascular diseaseTrial design
Design and rationale of the clinical trial to obtain the highest efficacy of dual antiplatelet therapy after carotid artery stenting in high bleeding risk patients (CHET): A multicenter, randomized, open-label, superiority trial
- multicenter, randomized, open-label, superiority trial
- design and rationale
- enrichment period of 30 days dual antiplatelet therapy (DAPT) before 1:1 randomization
Study context
- Population
- Patients with high bleeding risk (HBR) undergoing carotid artery stenting (CAS)final target (778 per group), allowing 2% dropout, 328 participants enrolled as of February 5, 2026
- Participants
- 1,556 patients
- Planned comparison
- abbreviated DAPT followed by SAPT compared to prolonged DAPT
- SAPTn = 778
- DAPTn = 778
- Primary endpoint
- Clinically significant bleeding (BARC 2, 3, or 5) (primary safety endpoint)
- Follow-up
- From day 30 to 12 months post-CAS
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Enrollment status · As of February 5, 2026
- participants enrolled
- 328
- enrollment began July 15, 2024; expected completion November 2029, follow-up by December 2030
Original publication
Design and rationale of the clinical trial to obtain the highest efficacy of dual antiplatelet therapy after carotid artery stenting in high bleeding risk patients (CHET): A multicenter, randomized, open-label, superiority trial. Am Heart J. Published 7 March 2026. doi:10.1016/j.ahj.2026.107418
Summarised from the published abstract; every number is checked against it